African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2198

Full Length Research Paper

Distributional characteristics of vesicular monoamine transporter 2 in human embryonic brain and their correlation with Parkinson’s disease

Xiangyang Tian1, Zhujuan Sun2, Xinsheng Ding3, Min Min3 and Xingzhen Sun4*
1Department of Neurology, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, Jiangsu 223300, P.R. China. 2Department of Orthopedics, Si Chuan Kang Gu Hospital, Cheng Du, Si Chuan 610041, P.R. China. 3Department of Neurology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China. 4Department of Pediatrics, Huai’an First People’s Hospital, Nanjing Medical University,6 Beijing Road West, Huai’an, Jiangsu 223300, P.R. China.
Email: [email protected]

  •  Accepted: 17 August 2012
  •  Published: 15 September 2012

Abstract

The aim of this study was to observe the distributional characteristics of vesicular monoamine transporter 2 (VMAT2), in human embryonic brain tissues and explore the relationship of these characteristics with Parkinson’s disease (PD). The distribution of VMAT2 and tyrosine hydroxylase (TH) in substantia nigra pars compacta (SNC), ventral tegmental area (VTA) and locus coeruleus (LC) of human embryonic brains of different gestational ages was observed using immunohistochemistry and western blot analysis. VMAT2 expression in SNC was significantly lower than that in VTA and LC (P < 0.05). VMATexpression in SNC is lower than that in VTA and LC. The weakened protective function of VMAT2 may be an important cause for the selective loss of dopaminergic neurons in SNC caused by PD.

 

Key words: Parkinson’s disease, vesicular monoamine transporter 2 (VMAT2), immunohistochemistry, tyrosine hydroxylase, human fetus.